CS212234B2 - Method of making the immunotherapeutical means against the infection decease uf urine and digesting ways - Google Patents
Method of making the immunotherapeutical means against the infection decease uf urine and digesting ways Download PDFInfo
- Publication number
- CS212234B2 CS212234B2 CS805266A CS526680A CS212234B2 CS 212234 B2 CS212234 B2 CS 212234B2 CS 805266 A CS805266 A CS 805266A CS 526680 A CS526680 A CS 526680A CS 212234 B2 CS212234 B2 CS 212234B2
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- nctc
- lysate
- sodium
- water
- escherichia coli
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 208000015181 infectious disease Diseases 0.000 title description 2
- 210000002700 urine Anatomy 0.000 title 1
- 239000006166 lysate Substances 0.000 claims abstract description 31
- 241000588724 Escherichia coli Species 0.000 claims abstract description 7
- 208000035404 Autolysis Diseases 0.000 claims abstract description 6
- 206010057248 Cell death Diseases 0.000 claims abstract description 6
- 230000028043 self proteolysis Effects 0.000 claims abstract description 6
- 230000009089 cytolysis Effects 0.000 claims abstract description 5
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 4
- 239000001963 growth medium Substances 0.000 claims abstract description 4
- 230000002485 urinary effect Effects 0.000 claims abstract description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 3
- 210000001635 urinary tract Anatomy 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 239000002609 medium Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 235000013372 meat Nutrition 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 235000015097 nutrients Nutrition 0.000 claims description 3
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 2
- 229920001817 Agar Polymers 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 241000206672 Gelidium Species 0.000 claims description 2
- 235000010419 agar Nutrition 0.000 claims description 2
- 229940041514 candida albicans extract Drugs 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 239000001540 sodium lactate Substances 0.000 claims description 2
- 229940005581 sodium lactate Drugs 0.000 claims description 2
- 235000011088 sodium lactate Nutrition 0.000 claims description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 2
- 235000019157 thiamine Nutrition 0.000 claims description 2
- 239000011721 thiamine Substances 0.000 claims description 2
- 239000012138 yeast extract Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 claims 1
- 238000000855 fermentation Methods 0.000 claims 1
- 230000004151 fermentation Effects 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 238000009630 liquid culture Methods 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 235000021419 vinegar Nutrition 0.000 claims 1
- 239000000052 vinegar Substances 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract 2
- 241000699670 Mus sp. Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 239000004251 Ammonium lactate Substances 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010061126 Escherichia infection Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 206010064921 Urinary tract inflammation Diseases 0.000 description 1
- 229940059265 ammonium lactate Drugs 0.000 description 1
- 235000019286 ammonium lactate Nutrition 0.000 description 1
- RZOBLYBZQXQGFY-HSHFZTNMSA-N azanium;(2r)-2-hydroxypropanoate Chemical compound [NH4+].C[C@@H](O)C([O-])=O RZOBLYBZQXQGFY-HSHFZTNMSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 208000020612 escherichia coli infection Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH692479A CH639852A5 (fr) | 1979-07-26 | 1979-07-26 | Medicament contre les maladies infectieuses des voies urinaires et digestives. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CS212234B2 true CS212234B2 (en) | 1982-03-26 |
Family
ID=4317195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS805266A CS212234B2 (en) | 1979-07-26 | 1980-07-25 | Method of making the immunotherapeutical means against the infection decease uf urine and digesting ways |
Country Status (16)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2550707B1 (fr) * | 1983-08-17 | 1986-02-28 | Lipha | Medicament immunomodulateur d'origine biologique et son procede de preparation |
| US4740585A (en) * | 1984-07-30 | 1988-04-26 | The Board Of Trustees Of The Leland Stanford Junior University | Synthetic vaccine against urinary infections |
| WO2004112833A1 (en) | 2003-06-23 | 2004-12-29 | Biotech Tools Sa | Epitope composition for sublingual, buccal or enteric administration prepared by hydrolysis of antigenic structures with chymotrypsin |
| ES2664990T3 (es) * | 2007-03-05 | 2018-04-24 | Om Pharma | Extracto bacteriano para trastornos del tracto digestivo o urinario y procedimiento para su preparación |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1336015A (en) * | 1970-06-03 | 1973-11-07 | Unilever Ltd | Rearing pigs |
| BE789864A (fr) * | 1971-10-14 | 1973-04-09 | Unilever Nv | Elevage des veaux |
| US3911109A (en) * | 1971-10-14 | 1975-10-07 | Lever Brothers Ltd | Rearing calves |
| JPS5219927B2 (enrdf_load_stackoverflow) * | 1972-06-08 | 1977-05-31 | ||
| GB1462384A (en) * | 1973-04-12 | 1977-01-26 | Unilever Ltd | Rearing of lambs |
| GB1560934A (en) * | 1975-05-07 | 1980-02-13 | Unilever Ltd | Methods for the resistance of non-human mammals to gastro-intestinal disorders |
| US4141970A (en) * | 1975-05-07 | 1979-02-27 | Internationale Octrooimaatschappij "Octropa" B.V. | Method for enhancing the resistance of new born mammalian young to gastro-intestinal infections |
| US4136167A (en) * | 1975-06-12 | 1979-01-23 | Internationale Octrooi Maatschappij "Octropa" B.V. | Process for reducing the incidence of neonatal diarrhoea in pigs |
| GB1581776A (en) * | 1976-08-18 | 1980-12-17 | Smith Kline Rit | Vaccines against oedema disease of piglets |
-
1979
- 1979-07-26 CH CH692479A patent/CH639852A5/fr not_active IP Right Cessation
-
1980
- 1980-05-21 DE DE19803019448 patent/DE3019448A1/de active Granted
- 1980-05-28 ES ES491920A patent/ES8104402A1/es not_active Expired
- 1980-06-06 FR FR8012677A patent/FR2462164A1/fr active Granted
- 1980-07-10 HU HU801726A patent/HU181725B/hu unknown
- 1980-07-14 DD DD222593A patent/DD153192A5/de not_active IP Right Cessation
- 1980-07-22 RO RO80101780A patent/RO80054A/ro unknown
- 1980-07-24 IT IT49314/80A patent/IT1143025B/it active
- 1980-07-24 BE BE0/201514A patent/BE884456A/fr not_active IP Right Cessation
- 1980-07-24 PL PL1980225853A patent/PL127520B1/pl unknown
- 1980-07-25 AR AR281940A patent/AR222887A1/es active
- 1980-07-25 JP JP10231580A patent/JPS5622733A/ja active Granted
- 1980-07-25 CS CS805266A patent/CS212234B2/cs unknown
- 1980-07-25 PT PT71612A patent/PT71612A/pt unknown
- 1980-07-25 YU YU1896/80A patent/YU42532B/xx unknown
- 1980-07-25 GB GB8024420A patent/GB2054374B/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| GB2054374B (en) | 1983-06-22 |
| IT1143025B (it) | 1986-10-22 |
| PL127520B1 (en) | 1983-11-30 |
| RO80054A (ro) | 1982-10-26 |
| PT71612A (fr) | 1980-08-01 |
| HU181725B (en) | 1983-11-28 |
| AR222887A1 (es) | 1981-06-30 |
| FR2462164A1 (fr) | 1981-02-13 |
| PL225853A1 (enrdf_load_stackoverflow) | 1981-05-08 |
| DD153192A5 (de) | 1981-12-30 |
| FR2462164B1 (enrdf_load_stackoverflow) | 1983-08-05 |
| DE3019448A1 (de) | 1981-02-12 |
| GB2054374A (en) | 1981-02-18 |
| ES491920A0 (es) | 1981-04-01 |
| YU42532B (en) | 1988-10-31 |
| ES8104402A1 (es) | 1981-04-01 |
| CH639852A5 (fr) | 1983-12-15 |
| JPS5622733A (en) | 1981-03-03 |
| DE3019448C2 (enrdf_load_stackoverflow) | 1987-07-30 |
| IT8049314A0 (it) | 1980-07-24 |
| YU189680A (en) | 1983-06-30 |
| JPH0255407B2 (enrdf_load_stackoverflow) | 1990-11-27 |
| BE884456A (fr) | 1980-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1246445A (en) | Intestinal microflora-improving agent | |
| JPH0648979B2 (ja) | アシドフイルス菌株培養物と同菌株の単離方法及び同菌株の細菌による治療方法 | |
| JPH02503800A (ja) | 炎症過程及びアレルギー性疾患の予防及び治療のための細菌性製剤 | |
| CS212234B2 (en) | Method of making the immunotherapeutical means against the infection decease uf urine and digesting ways | |
| JP3002552B2 (ja) | 皮膚炎治療薬 | |
| Ferraz et al. | Rothia dentocariosa endocarditis and aortic root abscess | |
| US4223040A (en) | Lauric acid for the prevention and treatment of mycobacterial diseases | |
| RU2123345C1 (ru) | Средство для лечения дисбактериоза | |
| Danø et al. | Antibiotic treatment with pivampicillin chloride in respiratory and urinary tract infections | |
| PL126416B1 (en) | Method of obtaining immunobiotherapeutic preparation counteractive against respiratory system diseases | |
| SU1487815A3 (ru) | Cпocoб пoлучehия биoлoгичeckи aktиbhoгo beщectba, oблaдaющeгo иmmуhoctиmулиpующиm дeйctbиem | |
| US20070207198A1 (en) | Use Of N-Acety1-D-Glucosamine In The Manufacture Of Medicaments For Anti-Tumors And Anti-Metastasis | |
| GB2077101A (en) | Antiallergic composition containing streptococci | |
| CN113521262A (zh) | 一种具有抗炎效果的溶菌酶制剂 | |
| TW200412989A (en) | Gamma delta T cell immunoactivity enhancers containing extract of Lentinus edodes mycelium | |
| Iyengar et al. | Plumbago zeylanica L.(Chitrak) a gastrointestinal flora normaliser | |
| CN119679857B (zh) | 一种抑制魏氏梭菌的组合物及其制备方法和应用 | |
| RU2101020C1 (ru) | Препарат, обладающий иммуностимулирующим действием | |
| WO2024237693A2 (ko) | 골관절염 개선 효과를 가진 발효 노니 농축액을 포함하는 조성물 | |
| GB2132481A (en) | Pharmaceutical compositions containing human pepsin or pepsin-like enzymes | |
| US20050119224A1 (en) | Use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for adjuvant treatment of perianal disease | |
| Ebringer et al. | Effect of trypacidin on Toxoplasma gondii in tissue culture and in mice | |
| JP2847204B2 (ja) | 生産体としてのフサリウム菌類株の利用及びその適応原及び免疫変成効果を有する塩基に基づいた製法 | |
| CN120168547A (zh) | 生物制剂及其制备方法与其在制备抑制大肠杆菌的产品中的应用 | |
| JP2002193828A (ja) | 活性型インターロイキン１２産生誘導剤および免疫賦活剤 |